Go Ad-Free
logoThe People's Perspective on Medicine

Actos Under Fire

The diabetes drug Avandia has taken a lot of heat in recent years because it has been linked to a higher risk of heart attacks. The FDA has just decided that the drug will be severely restricted only to patients who don’t respond well to other diabetes drugs.
Its chief competitor, Actos, has filled the void and captured much of the diabetes drug market share even though it too has a strict warning about causing or exacerbating heart failure. Now, the FDA has added another concern to the Actos prescribing dilemma. Data half way through a ten-year trial suggests that people taking Actos for long periods of time may have a higher risk of bladder cancer. The FDA is not ready to say that Actos actually causes cancer, but it will continue to monitor the data from the long-term study. The agency promises to update the public when it has additional information.

Rate this article
0- 0 ratings
About the Author
Terry Graedon, PhD, is a medical anthropologist and co-host of The People’s Pharmacy radio show, co-author of The People’s Pharmacy syndicated newspaper columns and numerous books, and co-founder of The People’s Pharmacy website. Terry taught in the Duke University School of Nursing and was an adjunct assistant professor in the Department of Anthropology. She is a Fellow of the Society of Applied Anthropology. Terry is one of the country's leading authorities on the science behind folk remedies..
Tired of the ads on our website?

Now you can browse our website completely ad-free for just $5 / month. Stay up to date on breaking health news and support our work without the distraction of advertisements.

Browse our website ad-free
Join over 150,000 Subscribers at The People's Pharmacy

We're empowering you to make wise decisions about your own health, by providing you with essential health information about both medical and alternative treatment options.